Dr. Gregory Berk
Bind Therapeutics now, and the company has announced Dr. Gregory Berk – an oncology veteran with over 20 years of experience – will serve as the new Chief Medical Officer.
Berk comes from his role at Takeda acquired clinical stage company, Intellikine and the pleasure of this new appointment was announced by Bind’s CEO, Scott Minick, who added: “Greg’s clinical vision and proven leadership, as well as his extensive medical and research experience, will strengthen our clinical development efforts and support the future progress of our product pipeline.”